Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SHOP -19.2%, DT -15.4%, DRVN -12.7%, CWH -11.2%, ZBRA -10.3%, VITL -9.6%, IT -8.4%, PLTR -7.3%, TVTX -7.0%, CLVT -4.8%, YUMC -4.3%, BMRN -4.2%, WAY -4.1%, AAPL -3.9%, PPLI -3.7%, RYTM -3.7%, HSIC -3.6%, KNF -3.0%, ARVN -2.9%, IAUX -2.9%, AESI -2.8%, KMX -2.8%, BWXT -2.7%, VSNT -2.5%, SBAC -2.4%, MSA -2.2%, APTV -2.2%, CALX -1.7%, BALL -1.6%, NMFC -1.5%, SBRA -1.5%, LDOS -1.5%, UPST -1.4%, UDR -1.4%, APO -1.2%, CRC -1.0%
Other news:
- IFRX -5.7% (Plans two Phase II izicopan trials in 2027, with initial data expected in 2028.)
- BIOA -5.0% (Novartis terminated its BrainTransporter collaboration after discontinuing the program; BioArctic retains the $30 million upfront payment.)
- INGM -4.0% (Prices an 11 million-share secondary at $25.90 and authorizes a concurrent 1 million-share repurchase.)
- DRUG -2.7% (FDA placed the planned U.S. Phase 2 BMB-101 DEE study on partial clinical hold over toxicity and data concerns.)
- CRM -2.4% (Signed a definitive agreement to acquire voice-first customer experience platform Cresta, with closing expected in fiscal Q1 2028.)
- ORCL -1.6% (Priced an 86.2 million-share offering at $116 and $10 billion of senior notes.)
- YEXT -1.3% (Completed its acquisition of Flamel.ai, adding localized paid-ad campaign management to its platform.)
- ULCC -1.1% (Names Michael Delehant COO and promotes James Fenner to chief revenue officer amid two senior departures.)
- ETSY -1.0% (A director sold 41,500 shares for approximately $3.82 million.)
Analyst comments:
- DHI -2.2% (Downgraded to Underperform from Market Perform at Raymond James.)
- MAN -1.7% (Downgraded to Neutral from Outperform at BNP Paribas, with a $52.50 price target.)